Sumitomo Mitsui DS Asset Management Company Ltd Has $20.28 Million Holdings in Boston Scientific Corporation $BSX

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 207,756 shares of the medical equipment provider’s stock after buying an additional 5,445 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Boston Scientific were worth $20,283,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Boston Scientific by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after purchasing an additional 2,545,381 shares in the last quarter. State Street Corp grew its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Boston Scientific by 2.0% in the second quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after buying an additional 622,602 shares in the last quarter. Norges Bank bought a new position in shares of Boston Scientific in the second quarter valued at about $2,089,937,000. Finally, Invesco Ltd. lifted its position in Boston Scientific by 1.4% during the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock worth $1,810,022,000 after buying an additional 226,578 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Activity

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 93,095 shares of company stock valued at $9,305,450. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BSX shares. UBS Group restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Leerink Partners raised their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, October 1st. Wells Fargo & Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Canaccord Genuity Group dropped their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Finally, BTIG Research reiterated a “buy” rating and issued a $132.00 price objective on shares of Boston Scientific in a research report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average price target of $125.21.

Boston Scientific Price Performance

Shares of BSX opened at $97.68 on Friday. The company’s 50-day moving average is $97.58 and its 200-day moving average is $100.78. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96. The firm has a market capitalization of $144.80 billion, a PE ratio of 52.23, a PEG ratio of 1.74 and a beta of 0.67. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. Boston Scientific’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.